Tissue Repair Ltd (TRP) AI Stock Analysis

• Market Cap: AU$19.35M
• Dividend Yield: N/A
• Average Volume (3M): 93.72K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.38
• Revenue Growth: 178.06%
• EPS Growth: -2.49%
• Country: US
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.03
• Shares Outstanding: 60,464,844
• 10 Day Avg. Volume: 171,402
• 30 Day Avg. Volume: 93,720
• PEG Ratio: -1.06
• Price to Book (P/B): 0.80
• Price to Sales (P/S): 4.25
• P/FCF Ratio: -2.71
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: AU$0.31 ▼(-19.21% Downside)

The score is primarily held back by weak financial performance driven by sustained losses and negative free cash flow (cash runway/funding risk), despite strong recent revenue growth and a debt-free balance sheet. Technicals add support due to a clear uptrend and positive momentum signals, while valuation is constrained by negative earnings and no dividend.

Positive Factors

Revenue Acceleration

Sustained, sharp revenue growth demonstrates emerging commercial traction or successful clinical/commercial milestones. Over a 2–6 month horizon, this trend supports scale-up potential, validates product-market fit in target respiratory indications, and can underpin future margin and cash improvements if continued.

High Gross Margins

Consistently high gross margins indicate favorable unit economics and a potentially scalable platform. For a biotech commercializing proprietary therapeutics, high product-level margins can sustain profitability once fixed costs and R&D intensity moderate, improving long-term operating leverage if revenue growth persists.

Debt-Free Balance Sheet

Lack of financial leverage reduces bankruptcy and interest-rate risk, preserving strategic flexibility to fund R&D or commercialization via equity or partnerships. Over months, this debt-free position lowers fixed financial obligations and supports capacity to pursue licensing or clinical milestones without near-term debt servicing constraints.

Negative Factors

Persistent Operating Losses

Chronic operating losses erode retained earnings and limit the firm's ability to self-fund growth. Over the medium term, ongoing negative margins increase dependency on external capital, constrain reinvestment, and amplify dilution risk unless the company achieves sustained profitability or secures non-dilutive funding.

Negative Cash Generation

Consistent negative operating and free cash flow shortens runway and necessitates financing or partnerships. This structural cash burn limits strategic optionality, forces near-term capital raises that dilute shareholders, and could impede clinical programs or commercialization unless cash flow turns positive or external funding is secured.

Erosion of Equity

Material decline in book equity reflects cumulative losses and weak returns on capital, signaling persistent value erosion. Over months this undermines balance-sheet resilience, raises probability of future capital raises on dilutive terms, and highlights structural challenges converting R&D investment into shareholder value.

Tissue Repair Ltd Business Overview & Revenue Model

Company Description

Tissue Repair Ltd, a clinical stage biopharmaceutical company, developing advanced wound healing products for chronic wounds and the aftercare of cosmetic procedures in Australia. It is developing TR-987 and other dressing/matrices, including Glucoprime technology for the treatment of chronic wounds, burns, and other complex wounds; and TR Pro+ for aftercare of minimally invasive cosmetic procedures, as well as other products for veterinary, new bandage, scaffold products, and other therapeutic indications. The company was incorporated in 2012 and is headquartered in Sydney, Australia.

How the Company Makes Money

Tissue Repair Ltd generates revenue primarily through the sale of its proprietary therapeutic products to hospitals, clinics, and healthcare providers. These products are marketed and distributed both directly and through strategic partnerships with pharmaceutical companies and medical device distributors. TRP also earns income through licensing agreements, where it grants rights to other companies to use its patented technologies in exchange for royalties or upfront payments. Additionally, TRP may receive funding through research grants and collaborations with academic institutions or government agencies, which support the development of new therapies and expand its product pipeline.

Tissue Repair Ltd Financial Statement Overview

Summary

Revenue accelerated sharply into 2025 and gross margin is very high, but the company remains deeply unprofitable with persistent operating losses and negative margins. Cash burn is ongoing with negative operating and free cash flow, and equity has declined materially despite zero debt, indicating elevated funding/dilution risk if profitability does not improve.

Income Statement

Revenue has accelerated sharply into 2025 (A$2.63m vs A$0.15m in 2024), and gross margin is very high in the latest two years. However, profitability remains weak: EBIT and net income are deeply negative across the period, with 2025 net margin around -161% and persistent operating losses indicating the business is still in heavy investment mode with limited earnings visibility.

Balance Sheet

The balance sheet is conservatively levered with zero debt from 2022–2025 and a 0.0 debt-to-equity ratio in the most recent years, which meaningfully reduces financial risk. The key weakness is ongoing value erosion: equity has declined materially from ~A$27.1m (2021) to ~A$13.9m (2025), and return on equity is consistently negative, reflecting continued losses and potential future funding needs if cash burn persists.

Cash Flow

Cash generation remains negative, with operating cash flow and free cash flow consistently below zero (2025 operating cash flow about -A$3.7m; free cash flow about -A$4.1m). Free cash flow worsened in 2025 versus 2024 (down ~24%), pointing to rising cash burn. A partial positive is that free cash flow tracks net losses closely (free cash flow to net income near ~1.0–1.1), suggesting losses are not being heavily distorted by non-cash items, but the overall cash runway risk remains elevated.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.63M	2.63M	152.24K	3.08K	171.92K	152.64K
Gross Profit	2.63M	2.63M	150.51K	428.00	170.21K	152.64K
EBITDA	-4.72M	-4.72M	-6.51M	-5.14M	-7.01M	-189.44K
Net Income	-4.24M	-4.24M	-4.14M	-4.17M	-6.84M	-915.23K
Balance Sheet
Total Assets	14.57M	14.57M	19.39M	22.38M	25.90M	27.61M
Cash, Cash Equivalents and Short-Term Investments	12.32M	12.32M	16.44M	21.40M	25.46M	27.11M
Total Debt	0.00	0.00	0.00	0.00	0.00	7.50M
Total Liabilities	662.53K	662.53K	1.35M	497.35K	559.64K	536.00K
Stockholders Equity	13.91M	13.91M	18.04M	21.88M	25.34M	27.07M
Cash Flow
Free Cash Flow	-4.12M	-4.12M	-4.95M	-4.26M	-3.97M	-852.89K
Operating Cash Flow	-3.70M	-3.70M	-4.95M	-4.26M	-3.97M	-852.89K
Investing Cash Flow	-421.67K	-421.67K	-3.35K	-2.24K	-3.92K	5.00K
Financing Cash Flow	0.00	0.00	0.00	0.00	21.36M	7.46M

Tissue Repair Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.38
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:TRP, the sentiment is Negative. The current price of 0.38 is above the 20-day moving average (MA) of 0.35, above the 50-day MA of 0.34, and above the 200-day MA of 0.27, indicating a neutral trend. The MACD of -0.01 indicates Positive momentum. The RSI at 36.11 is Neutral, neither overbought nor oversold. The STOCH value of 9.06 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:TRP.

Tissue Repair Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TRP	51 Neutral	AU$19.35M	-4.35	-26.53%	―	178.06%	-2.49%
PTX	50 Neutral	AU$84.12M	-8.35	-49.72%	―	―	10.78%
CMB	48 Neutral	AU$13.78M	-2.33	-166.70%	―	―	―
BGT	46 Neutral	AU$9.15M	-2.54	―	―	―	―
AVE	44 Neutral	AU$36.73M	-9.09	-143.71%	―	306.88%	―
1AD	37 Underperform	AU$11.48M	-1.61	-628.72%	―	―	31.87%

Tissue Repair Ltd Corporate Events

Tissue Repair Limited Addresses ASX Price Query

Tissue Repair Limited has responded to an ASX price query, confirming that it is not aware of any undisclosed information that could explain recent trading activity in its securities. The company asserts compliance with listing rules and confirms that its responses have been authorized under its continuous disclosure policy.

Tissue Repair Ltd Announces Director’s Acquisition of Unlisted Options

Tissue Repair Ltd has announced a change in the director’s interest, specifically involving Patryk Kania, who has acquired 261,000 unlisted options. These options are exercisable at $1.15 and will expire on 26 November 2040, following approval at the company’s Annual General Meeting. This change reflects a strategic move in the company’s governance and could potentially impact its market operations by aligning director interests with long-term company performance.

Tissue Repair Ltd Announces Director’s Interest Change

Tissue Repair Ltd announced a change in the director’s interest, with Alistair McKeough acquiring 311,000 unlisted options and 30,000 ordinary fully paid shares. This change, approved by shareholders, reflects the company’s ongoing efforts to align its leadership’s interests with its strategic goals, potentially impacting its market positioning and stakeholder confidence.

Tissue Repair Limited Appoints New Auditor

Tissue Repair Limited has announced the appointment of Stantons International Audit and Consulting Pty Ltd as its new auditor, following the resignation of Pitcher Partners Sydney. This change, approved at the company’s Annual General Meeting, aligns with compliance requirements and has received necessary regulatory approvals. The appointment is expected to support the company’s ongoing operations and strategic goals.

Tissue Repair Ltd Successfully Passes All Resolutions at 2025 AGM

Tissue Repair Limited announced that all resolutions proposed at its 2025 Annual General Meeting were successfully carried. This includes the adoption of the remuneration report, election of new directors, appointment of auditors, and approval of options and incentive plans. The outcomes of these resolutions are expected to strengthen the company’s governance and operational strategies, potentially enhancing its market position and stakeholder confidence.

Tissue Repair Ltd Advances Clinical Trials and Expands Market Reach

Tissue Repair Ltd reported progress in its clinical trials for TR987®, with significant advancements in patient randomization and site activations across the U.S. and Australia. The company is on track with its regulatory submissions and has commenced a partnership with Advanced Cosmeceuticals Pty Ltd for TR Pro+®, expecting meaningful sales to begin in early 2026. Financially, the company reported a cash position of $10.3 million as of September 2025, with increased revenue from TR Pro+® sales and ongoing R&D investments.